drugset

drugset / Trial / NCT01720147

Quercetin in Children With Fanconi Anemia; a Pilot Study

NCT01720147 ↗

Phase 1 Completed 30 enrolled Children's Hospital Medical Center, Cincinnati Food and Drug Administration (FDA) · collab

NaSingle-groupOpen-labelPrevention

Summary

Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone marrow failure (BMF), congenital abnormalities and a predisposition to malignancy.

Timeline

Start: 2012-07
Primary completion: 2021-10-26
Completion: 2021-10-26

Publications

Mehta PA, Nelson A, Loveless S, Lane A, Fukuda T, Teusink-Cross A, Elder D, Lagory D, Miller E, Cancelas JA, Howell J, Zhao J, Mizuno K, Myers KC, Lake K, McIntosh K, Setchell KDR, Luebbering N, Edwards S, Chihanga T, Wells SI, Davies SM. Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia. Blood Adv. 2025 Apr 22;9(8):1927-1939. doi: 10.1182/bloodadvances.2024015053.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Quercetin	Small molecule	1500 mg	Oral

Indications